Infliximab Therapy for Rheumatic Diseases in Patients with Chronic Hepatitis B or C

Journal of Rheumatology

Volumn 31, Issue 1, 2004, Pages 107-109

  Oniankitan, Owonayo ^a   Duvoux, Christophe ^a   Challine, Dominique ^a   Mallat, Arianne ^a   Chevalier, Xavier ^a   Pawlotsky, Jean Michel ^a   Claudepierre, Pascal ^a,b  

^a Department of Rheumatology ^*

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

Hepatitis B; Hepatitis C; Infliximab therapy

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LAMIVUDINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ARTHROPATHY; ARTICLE; CASE REPORT; CHRONIC HEPATITIS; DISEASE ACTIVITY; DRUG SAFETY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; INFLAMMATION; LABORATORY TEST; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER TOXICITY; MALE; PRIORITY JOURNAL; RHEUMATIC DISEASE; TREATMENT OUTCOME; VIREMIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; MALE; RHEUMATIC DISEASES;

EID: 0346057892     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Maini R, St. Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study group. Lancet 1999;354:1932-9.
2. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
3. Van den Bosch F, Baeten D, Kruithof E, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000;59:428-33.
4. Brandt J, Haibel H, Cornely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumour necrosis factor α monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346-52.
5. Van Den Bosch F, Kruithof E, Baeten D, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002;46:755-65.
6. Braun J, Brandt J, Zink A, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
7. Conlon KC, Urba WJ, Smith JW 2nd, Steis RG, Longo DL, Clark JW. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 1990;65:2237-42.
8. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
9. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
10. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
11. Koziel MJ. Cytokines in viral hepatitis. Semin Liver Dis 1999;19:157-69.
12. Saleem G, Li SC, MacPherson BR, Cooper SM. Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: comment on the article by Charles, et al. Arthritis Rheum 2001;44:1966-8.
13. Campbell S, Ghosh S. Infliximab therapy for Crohn's diseases in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 2001;13:191-2.